| Literature DB >> 29053888 |
D Radzišauskienė1, K Žagminas2, L Ašoklienė2, A Jasionis3, R Mameniškienė3, A Ambrozaitis1, L Jančorienė1, D Jatužis3, I Petraitytė2, E Mockienė4.
Abstract
BACKGROUND ANDEntities:
Keywords: clinical forms; epidemiology; prognostic factors; tick-borne encephalitis
Mesh:
Year: 2017 PMID: 29053888 PMCID: PMC5814845 DOI: 10.1111/ene.13486
Source DB: PubMed Journal: Eur J Neurol ISSN: 1351-5101 Impact factor: 6.089
Figure 1Annual incidence of tick‐borne encephalitis in Lithuania, 1970–2014 (n = 9370).
Figure 2Rates of confirmed reported TBE cases by age, 2005–2014.
Figure 3Seasonal distribution of confirmed TBE cases in Lithuania, 2005–2014.
Epidemiological, demographic data and the clinical course of tick‐borne encephalitis
| Study characteristic | Value, |
|---|---|
| Inhabitants of cities | 427 (60) |
| Receipt of tick bite/bites | 460 (64) |
| Milk‐borne infection | 49/625 (7.8) |
| Infected in living area | 223/528 (42.2) |
| Job‐related infection | 10/528 (1.9) |
| Incubation period (days) | 11.4 (2–41) |
| Biphasic course | 413 (58.1) |
| Duration of first stage, mean (min–max) (days) | 4.9 (1–19) |
| Interval between first and second stage, mean (min–max) (days) | 14.6 (3–100) |
| Patient's sex | |
| Male | 387 (54) |
| Age, median (min–max) (years) | 51 (18–85) |
| Clinical form of illness | |
| Meningitis | 66 (9.6) |
| Meningoencephalitis | 556 (81.3) |
| Meningoencephalomyelitis | 22 (3.2) |
| Encephalitis | 40 (5.8) |
| Symptoms and signs before hospitalization | |
| Fever | 709 (99.6) |
| Headache | 647 (90.9) |
| Vertigo | 288 (40.4) |
| Nausea/vomiting | 214 (30.1) |
| Muscle pain | 44 (6.2) |
| Diarrhoea | 10 (1.4) |
| Neurological symptoms and signs | 229 (32.2) |
Clinical presentation of central nervous system involvement (n = 712)
| Symptoms and signs |
| Duration of resolved symptoms, mean (max–min) (days) | Not resolved cases (%) |
|---|---|---|---|
| Meningeal signs | |||
| Overall | 474 (66.5) | 4.57 (<1–32) | 2/474 (0.4) |
| Neck stiffness | 442 (62.1) | 4.3 (<1–22) | 2/442 (0.5) |
| Kernig's sign | 331 (46.5) | 4.6 (<1–32) | 2/331 (0.6) |
| Ataxia | 579 (81.3) | 7.4 (<1–37) | 323/579 (55.3) |
| Tremor | 338 (47.5) | 6.2 (<1–42) | 163/338 (47.9) |
| Nystagmus | 219 (30.8) | 4.7 (<1–18) | 5/219 (2.3) |
| Epileptic seizures | 15 (2.1) | 3.25 (<1–15) | 0 |
| Parkinson's syndrome | 11 (1.5) | 7.2 (2–21) | 4/11 (36.4) |
| Pyramidal signs | 88 (8.1) | 5.3 (<1–16) | 2/88 (2.3) |
| Dysphagia | 14 (2) | 3.6 (<1–12) | 1/14 (7.1) |
| Altered consciousness | |||
| Quantitative (overall) | 171 (24) | 2.7 (<1–34) | 3/171 (1.7) |
| Somnolence | 151 (21.2) | 2.1 (<1–16) | 2/151 (1.3) |
| Sopor | 31 (4.4) | 2.5 (<1–8) | 1/31 (3.2) |
| Comatose | 11 (1.6) | 5.2 (1–17) | 3/11 (27.3) |
| Qualitative (overall) | 105 (14.8) | 3/105 (2.9) | |
| Agitation | 36 (5.1) | 1.7 (<1–10) | 1/36 (2.8) |
| Disorientation | 98 (13.8) | 3.3 (<1–40) | 3/98 (3) |
| Hallucinations | 7 (1) | 1 (<1–2) | 1/7 (14.3) |
| Cranial neuropathies (overall) | 159 (22.3) | ||
| Ocular motor paresis (III, IV, VI) | 52 (7.3) | 5.5 (<1–29) | 2/52 (3.8) |
| Facial weakness (VII) | 7 (1) | 4.5 (2–7) | 5/7 (71.4) |
| Hearing disturbance (VIII) | 16 (2.3) | 3 (3–3) | 14/16 (87.5) |
| Bulbar signs | 77 (10.8) | ||
| Dysphonia | 56 (7.9) | 8.1 (2–48) | 18/56 (32.1) |
| Dysarthria | 49 (6.9) | 8.2 (<1–48) | 13/49 (26.5) |
| Dysphagia | 12 (1.6) | 14 (2–48) | 7/12 (58.3) |
| Paresis of elevator muscles of head (XI) | 4 (0.6) | – | 4/4 (100) |
| Visual field defect (II) | 1 (0.1) | – | 1/1 |
| Anosmia (I) | 1 (0.1) | – | 1/1 |
| Masticatory muscle paresis (V) | 1 | – | 1/1 |
| Limb paresis (overall) | 45 (6.3) | – | 31/45 (68.9) |
| Spastic | 21 (3) | 6.5 (<1–20) | 7/21 (33.3) |
| Flaccid (overall) | 24 (3.4) | – | 24/24 (100) |
| Tetraparesis | 10 (1) | – | 10/10 (100) |
Prognostic factors for severe disease
| Variable | ORc | ORa | 95% CI |
|
|---|---|---|---|---|
| Sex | ||||
| Female | 1.0 | 1.0 | – | 0.27 |
| Male | 1.15 | 1.27 | 0.84–1.92 | |
| Age group (years) | ||||
| <40 | 1.0 | – | – | |
| 41–60 | 1.35 | 1.44 | 0.82–2.55 | 0.20 |
| 61+ | 2.24 | 2.10 | 1.04–3.73 | 0.036 |
| Comorbidities | ||||
| 0 | 1.0 | 1.0 | – | |
| 1 | 1.74 | 1.45 | 0.86–2.43 | 0.16 |
| 2 | 2.22 | 1.91 | 0.97–3.76 | 0.06 |
| 3 | 2.66 | 2.43 | 1.02–5.78 | 0.044 |
| 4+ | 3.15 | 2.05 | 0.72–5.84 | 0.18 |
| Delayed hospitalization | ||||
| 0–5 days | 1.0 | 1.0 | – | |
| 6+ | 0.93 | .71 | 0.45–1.12 | 0.14 |
| Cytosis | ||||
| <500 | 1.00 | 1.0 | 1.0 | |
| 500+ | 2.77 | 2.52 | 0.93–6.81 | 0.07 |
| Delayed immune response | ||||
| (IgM+, IgG−) | 3.27 | 2.37 | 1.05–5.39 | 0.04 |
N = 645. CI, confidence interval; ORc, crude odds ratio; ORa, adjusted odds ratio. Likelihood ratio χ 2 = 42.50, df 11, P < 0.0001. Hosmer–Lemeshow test χ2 = 5.99, df 8, P = 0.65. McFadden's R 2 = 0.068, model correctly classified 81.71%, area under the receiver operating curve 0.67.